Navigation Links
Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C
Date:4/17/2011

MYSTIC, Conn. and DUBLIN, April 18, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from its ANCHOR trial for the Company's lead product candidate, AMR101. The Phase 3 trial met its primary and secondary efficacy endpoints for both the 4 gram and 2 gram daily doses.

The purpose of the ANCHOR trial was to demonstrate that AMR101 is effective in reducing triglyceride levels in patients with high triglycerides without increasing LDL-C ("bad cholesterol") levels in patients on background statin therapy. The ANCHOR trial investigated AMR101 as a treatment for high triglycerides (≥200 and <500mg/dL) in 702 patients with mixed dyslipidemia (two or more lipid disorders) on background statin therapy at LDL-C (low-density lipoprotein cholesterol) goal who were at high risk of cardiovascular disease. The majority of these patients were diabetic (73%). This is the largest trial with omega-3 therapy conducted in this important patient population. All patients were on background statin therapy with simvastatin, atorvastatin or rosuvastatin. Despite the benefits of statin therapy, patients in this population have significant residual risk for cardiovascular events. The trial's primary endpoint was defined as the percentage change in triglyceride levels from baseline compared to placebo after twelve weeks of treatment. In addition, the study was powered to demonstrate a lack of LDL-C elevating effect with AMR101 compared to placebo. The trial was conducted under a Special Protocol Assessment (SPA) agreement with the FDA.

Triglyceride Reduction Levels Exceeded Company Expectations

The primary endpoint for triglyceride change was achieved at both 4 grams and 2 grams per day with median placebo-adjusted
'/>"/>

SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 Touro University California,s College of ... as the recipient of a $150,000 grant by the ... University to increase research and classroom space on its ... for the study of health sciences, and will help ... and interests of our students," said Shelley Berkley ...
(Date:7/31/2014)... Colo. , July 31, 2014  Cannabis ... in cannabis formulation-based drug development and related consulting, ... production of multiple strains of cannabis and European ... to select the best strains for development of ... the cannabis formulations to market for critical ailments ...
(Date:7/31/2014)... Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company ... conference call on Thursday, August 14, 2014, at 4:30 p.m. ... June 30, 2014. Financial results will be issued in a ... President and CEO James LaFrance will host the ... Date: Thursday, August 14, 2014 Time: 4:30 p.m. Eastern time ...
Breaking Medicine Technology:Touro University California Garners Grant From Long Foundation 2Cannabis Science Initiates Scientific Cultivation Programs to Test Multiple Strains of Cannabis to Obtain Extract Formulations for Clinical Drug Development Targeting Multiple Critical Ailments Starting with Cancer and Neurological Disorders 2Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
...  Eli Lilly and Company (NYSE: LLY ) has ... Women" list for the fourth consecutive year. ... Executives (NAFE), recognizes U.S. companies whose policies and practices encourage ... leadership, demonstrate that commitment. The NAFE Top Companies ...
... NEW YORK, Feb. 6, 2012 Faruqi & ... is investigating potential securities fraud at GenVec, Inc. ... (Logo:  http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... its executives violated federal securities laws by failing ...
Cached Medicine Technology:Lilly Recognized as a Top Company for Executive Women 2Faruqi & Faruqi, LLP Announces Investigation of GenVec, Inc. 2
(Date:7/31/2014)... Fitness on the Go in-home ... which now includes Ottawa along with all major cities ... fitness to clients in Ontario since 2012, but have ... a Canadian owned in-home fitness and personal training company ... and fitter lifestyle. , Fitness on the Go makes ...
(Date:7/31/2014)... Atlanta-based Jvion, a leader in clinical ... lessons in predictive population health analytics as part of ... analytics in healthcare. Ritesh Sharma, Jvion COO, commented, “it ... to understand the impact of and potential within predictive ... and a good portion of it is conflicting or ...
(Date:7/31/2014)... Morristown, NJ (PRWEB) July 31, 2014 ANS ... they receive about the ANS Skull Base Center and what ... the ANS Skull Base Surgery Center ?, Skull base ... reaches the undersurface of the brain, an area historically considered ... way to access these areas was by retracting healthy brain ...
(Date:7/31/2014)... During the July 2014 board meeting of the ... executive director of the Mesothelioma Applied Research Foundation, Mary ... promising clinical trials to choose from than ever before. ... have been reporting increased survival and response rates. Some ... is within the field of immunotherapy. One trial, ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 ProPilates ... with a comprehensive approach to the entire body by ... Pilates studio in South Florida with expectations of continual ... , “We are honored to be a part of ... are proactively seeking a way to improve their health ...
Breaking Medicine News(10 mins):Health News:Fitness on the Go Grows to Ottawa 2Health News:Jvion Releases Top Three Lessons in Predictive Population Health Analytics 2Health News:Jvion Releases Top Three Lessons in Predictive Population Health Analytics 3Health News:Dr. Yaron Moshel of Atlantic NeuroSurgical Specialists (ANS) Discusses Brain Tumor Surgery 2Health News:Dr. Yaron Moshel of Atlantic NeuroSurgical Specialists (ANS) Discusses Brain Tumor Surgery 3Health News:‘More Promising Mesothelioma Clinical Trials than Ever Before,’ Says Expert 2Health News:‘More Promising Mesothelioma Clinical Trials than Ever Before,’ Says Expert 3Health News:Fort Lauderdale Pilates Studio ProPilates Reaches Record Growth with Launch of Spinlates by Pilates Powerhouse and Studio Owner, Tonka Cascais 2Health News:Fort Lauderdale Pilates Studio ProPilates Reaches Record Growth with Launch of Spinlates by Pilates Powerhouse and Studio Owner, Tonka Cascais 3
... , , PITTSBURGH , Jan. 14 ... union, today said that the union is pleased with the progress ... for working families. , (Logo: http://www.newscom.com/cgi-bin/prnh/20080131/DC12982LOGO ) , ... for generations we,ve been fighting for health care for all in ...
... , Jan. 14 Today, attorneys with ... a class action law suit and preliminary injunction on ... Angeles Regional Center (ELARC) for unlawfully terminating the most ... through which the state provides statutorily-required services to people ...
... WASHINGTON , Jan. 14 For those who may ... dealing with the images of the Haiti earthquake aftermath, ... from afar and tips for recovering from disasters on its Web ... lives, the wounded and the destruction of homes and communities as ...
... Jan. 14 As the House and Senate work ... Liability and Access (HCLA) sent a letter to House Speaker ... emphasizing the need to retain and strengthen current medical liability reform ... climate has prevented comprehensive medical liability reform efforts from passing, we ...
... , Jan. 14 Resident Sabrina Ahmed ... slowly to get anything done in her home. To make things easier ... wheelchair through her insurance coverage. Unfortunately, the chair didn,t work, and she ... to call " 7 On Your Side " news (WSPA-TV). WSPA Anchor ...
... may be unfounded, agency says , THURSDAY, Jan. 14 ... on Thursday said it found no good evidence that ... use it to help control chronic obstructive pulmonary disease ... early 2008 by the drug,s maker, "suggesting a small ...
Cached Medicine News:Health News:Health Reform Tax Changes: Good Progress for Workers; Union to Keep Working for Better Bill 2Health News:Class Action Suit Filed to Defend Rights of Children With Autism to Vital, Cost-Saving Treatment 2Health News:Class Action Suit Filed to Defend Rights of Children With Autism to Vital, Cost-Saving Treatment 3Health News:APA Offers Resources on Managing Traumatic Stress in Wake of Haiti Earthquake 2Health News:APA Offers Resources on Managing Traumatic Stress in Wake of Haiti Earthquake 3Health News:Broad Health Coalition Continues to Press for Medical Liability Reform 2Health News:The SCOOTER Store Answers Local News Viewer's Need for Power Chair 2Health News:The SCOOTER Store Answers Local News Viewer's Need for Power Chair 3Health News:Leading COPD Drug Won't Harm Heart: FDA 2Health News:Leading COPD Drug Won't Harm Heart: FDA 3Health News:Leading COPD Drug Won't Harm Heart: FDA 4
Adjustable Velcro© closures at crown and behind the neck distinguish this immediate post-op face and chin garment for maximum support and compression....
Facial Wrap...
Very compressive support for submental liposuction...
Ideal for autoplasty and liposuction of chin and cheeks...
Medicine Products: